SCIENTIFIC INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SCIENTIFIC INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.05M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.80M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.24M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $11.40M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $9.78M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $7.78M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $10.20M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $8.48M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $8.15M | Sep 28, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.32M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $5.74M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $4.98M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $3.94M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $4.37M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $3.22M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $2.88M | Sep 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.22M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.45M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.09M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.08M) | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | ($13.67M) | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | ($3.67M) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | ($703.3K) | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $645.6K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($160.5K) | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | ($72.6K) | Sep 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.22M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($9.26M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.14M) | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | ($11.54M) | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | ($4.71M) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | ($663.5K) | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $776.1K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | ($5.5K) | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | ($160.4K) | Sep 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.90M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.57M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.40M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $2.87M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $1.62M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $1.14M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $530.5K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $520.9K | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $437.5K | Sep 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($3.68M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($6.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.85M) | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | ($5.19M) | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | ($3.30M) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | ($168.1K) | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $1.16M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $256.9K | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $46.1K | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | $880.4K | Sep 28, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $98.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $131.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $253.0K | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $757.6K | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $198.7K | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $50.9K | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $187.8K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $61.4K | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $17.0K | Sep 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.56M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.73M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.07M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $21.01M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $29.01M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $14.80M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $8.28M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $7.33M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $6.83M | Sep 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.44M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.28M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $3.47M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $2.78M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $3.08M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $1.94M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $1.62M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $999.7K | Sep 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $13.89M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $14.79M | Mar 31, 2025 |
| FY2023 | Jun 30, 2022 | $17.54M | Jul 18, 2024 |
| FY2023 | Jun 30, 2021 | $26.22M | Jul 18, 2024 |
| FY2022 | Jun 30, 2020 | $11.72M | Sep 28, 2022 |
| FY2020 | Jun 30, 2019 | $6.34M | Oct 14, 2021 |
| FY2020 | Jun 30, 2018 | $5.70M | Oct 9, 2020 |
| FY2019 | Jun 30, 2017 | $5.83M | Oct 4, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.3K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $115.3K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $115.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $115.3K | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $115.3K | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $4.40M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $257.3K | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $705.3K | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $705.3K | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $705.3K | Sep 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.15M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($33.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($27.49M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.40M) | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | ($14.32M) | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | ($651.1K) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | $3.02M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | $3.72M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | $3.13M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | $3.29M | Sep 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $1.93M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | $2.97M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | $9.68M | Sep 28, 2022 |
| FY2022 | Jun 30, 2020 | $7.56M | Sep 28, 2022 |
| FY2020 | Jun 30, 2019 | $1.60M | Oct 14, 2021 |
| FY2020 | Jun 30, 2018 | $1.05M | Oct 9, 2020 |
| FY2019 | Jun 30, 2017 | $1.03M | Oct 4, 2019 |
| FY2018 | Jun 30, 2016 | $1.25M | Sep 28, 2018 |
| FY2017 | Jun 30, 2015 | $482.0K | Sep 28, 2017 |
| FY2016 | Jun 30, 2014 | $493.7K | Oct 11, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $0 | Sep 28, 2018 |
| FY2017 | Jun 30, 2017 | $5.8K | Sep 28, 2017 |
| FY2016 | Jun 30, 2016 | $12.5K | Oct 11, 2016 |
| FY2016 | Jun 30, 2015 | $0 | Oct 11, 2016 |
| FY2014 | Jun 30, 2014 | $0 | Sep 26, 2014 |
| FY2013 | Jun 30, 2013 | $26.7K | Sep 27, 2013 |
| FY2012 | Jun 30, 2012 | $105.0K | Sep 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2021 | (1) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | 0 | Oct 9, 2020 |
| FY2020 | Jun 30, 2019 | 0 | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Oct 11, 2016 |
| FY2015 | Jun 30, 2014 | 0 | Sep 30, 2015 |
| FY2014 | Jun 30, 2013 | 0 | Sep 26, 2014 |
| FY2013 | Jun 30, 2012 | 0 | Sep 27, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2022 | Jun 30, 2021 | (1) | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | 0 | Oct 9, 2020 |
| FY2020 | Jun 30, 2019 | 0 | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | 0 | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Sep 28, 2018 |
| FY2017 | Jun 30, 2016 | 0 | Sep 28, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Oct 11, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.93M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 10.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 7.00M | Jul 18, 2024 |
| FY2023 | Jun 30, 2022 | 7.00M | Jul 18, 2024 |
| FY2022 | Jun 30, 2021 | 6.46M | Sep 28, 2022 |
| FY2020 | Jun 30, 2020 | 2.86M | Oct 14, 2021 |
| FY2020 | Jun 30, 2019 | 1.49M | Oct 9, 2020 |
| FY2019 | Jun 30, 2018 | 1.51M | Oct 4, 2019 |
| FY2018 | Jun 30, 2017 | 1.51M | Sep 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Jun 30, 2012 | $59.8K | Sep 27, 2012 |
| FY2012 | Jun 30, 2011 | $107.7K | Sep 27, 2012 |